On February 3, 2021, R2 Dermatology Incorporated closed the transaction. The company has received $10,000,000 in its third and final tranche. The company has raised the round at post-money valuation is $113,000,000.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.88 CNY | +2.85% | +3.39% | -18.28% |
04-25 | Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-18 | Huadong Medicine's 2023 Profit Jumps 14% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.28% | 7.97B | |
+14.82% | 69.5B | |
-2.11% | 24.09B | |
+8.13% | 8.2B | |
-0.98% | 7.84B | |
+19.12% | 4.32B | |
0.00% | 4.19B | |
-3.02% | 3.89B | |
+23.97% | 3.62B | |
+8.64% | 3.41B |
- Stock Market
- Equities
- 000963 Stock
- News Huadong Medicine Co., Ltd
- R2 Technologies, Inc. announced that it has received $30 million in funding from Huadong Medicine Co., Ltd